An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Inclusion Criteria:

• Menopausal women aged 50 years or more diagnosed with dyslipidemia

• Menopause was defined as the condition of not having menstruation for 1 yearwith no specific cause or being diagnosed with menopause at the discretion ofan investigator (except for the case of being diagnosed with menopause for asurgical reason within 5 years), and the menopausal status is confirmed as ofthe Mevalotin® Tablet administration start date (Index date).

• Patients who are determined to be prescribed with Mevalotin® Tablet at thediscretion of an investigator or patients who started Mevalotin® Tabletadministration within 6 weeks prior to enrollment in this observational study (however, in case of patients switching from statins to Mevalotin® Tablet, onlythose who receive from low/intermediate intensity statins treatment tolow/intermediate intensity statins treatment can be enrolled in this study)

• Patients who provided voluntary written consent to take part in this observationalstudy

Exclusion Criteria:

• Patients with a history of cancer within 5 years (however, patients with a historyof brain tumor, breast cancer, uterine cancer, ovarian cancer, or endometrial cancerare excluded from enrollment regardless of duration.)

• Patients who received hormone replacement therapy within 1 year of enrollment

• Patients who are determined to be ineligible for participation in this observationalstudy